On the crest of a wave; as CAR-T gathers speed, is future usage expected to be robust?
Kymriah (Novartis) and Yescarta (Gilead/Kite) have blazed a trail for anti-CD19 CAR-T therapies, and both are now sweeping across the US and Europe. There’s no doubt that the future for CAR-T therapies is bright due to them delivering significant improvements in clinical outcomes in difficult to treat indications. But what do treating physicians think about how CAR-T is being used today? What are the key challenges and opportunities that exist for this novel technology, in terms of patient selection and logistics? And how is the landscape likely to evolve in the future, both in terms of CAR-T therapy prescribing and the impact on other treatment modalities?
FirstWord carried out in-depth quantitative research with over 200 medical oncologists, haemato-oncologists and haematologists in the US, France, Germany and the UK to understand physician awareness and enthusiasm levels for CAR-T therapies, what could be done to improve this, and expectations for the future of the treatment landscape. The key issues explored included:
This physicians insight into current and future prescribing patterns for CAR-T therapies in haematological cancers makes important reading for pharma, not only for companies actively engaged in the development and commercialisation of CAR-T therapies, but also for key stakeholders seeking in-depth, quantitative insights on how the CAR-T landscape is evolving, and how things are likely to change in the future. Find out what treating physicians are saying about CAR-T, what the key drivers and resistors are to its use today and in the future, and what promising next-generation approaches are generating the most excitement. Download CAR-T Therapies in Haematological Cancers (Physician Survey) and start deciphering what’s next for this critically important treatment approach in haematological cancer. In this report you can expect to find:
We surveyed 205 medical oncologists, haemato-oncologists and haematologists in the US, France, Germany and the UK (n=104 physicians in US, n=101 physicians in France, Germany, the UK). All respondents have been practicing for an average of 16 years, devote over 80% of their time to patient care and play an active prescribing role for haematological cancers, specifically leukaemias, lymphomas or myeloma, and are familiar CAR-T cell therapy.
This unique research will help you understand how treating physicians see the future CAR-T therapy market evolving, and what next-generation approaches are igniting the most excitement. In CAR-T Therapies in Haematological Cancers (Physician Survey) you will also learn about key challenges and opportunities facing this novel technology, what the key drivers and resistors to usage are, and how things differ between the US and Europe.
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
Learn more at www.firstwordgroup.com.
All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved